Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial-Reference-Cited by-同舟云学术

Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial

Published:2016-05 Issue:5 Volume:3 Page:e217-e227
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Ferreri Andrés J M,Cwynarski Kate,Pulczynski Elisa,Ponzoni Maurilio,Deckert Martina,Politi Letterio S,Torri Valter,Fox Christopher P,Rosée Paul La,Schorb Elisabeth,Ambrosetti Achille,Roth Alexander,Hemmaway Claire,Ferrari Angela,Linton Kim M,Rudà Roberta,Binder Mascha,Pukrop Tobias,Balzarotti Monica,Fabbri Alberto,Johnson Peter,Gørløv Jette Sønderskov,Hess Georg,Panse Jens,Pisani Francesco,Tucci Alessandra,Stilgenbauer Stephan,Hertenstein Bernd,Keller Ulrich,Krause Stefan W,Levis Alessandro,Schmoll Hans J,Cavalli Franco,Finke Jürgen,Reni Michele,Zucca Emanuele,Illerhaus Gerald

Publisher

Elsevier BV

Subject

Hematology

Reference30 articles.

1. Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology;Hoang-Xuan;Lancet Oncol,2015

2. How I treat primary CNS lymphoma;Ferreri;Blood,2011

3. Primary central nervous system lymphoma: overview of current treatment strategies;Brastianos;Hematol Oncol Clin North Am,2012

4. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial;Ferreri;Lancet,2009

5. Progress in primary CNS lymphoma;O'Brien;Lancet,2009

Cited by 466 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sintilimab (anti-PD-1 antibody) combined with high-dose methotrexate, temozolomide, and rituximab (anti-CD20 antibody) in primary central nervous system lymphoma: a phase 2 study;Signal Transduction and Targeted Therapy;2024-09-04

2. Clinical Presentation, Management, and Outcome in Neurolymphomatosis;Neurology;2024-08-27

3. Prognostic Impacts of Age, Diagnosis Time, and Relapses in Primary CNS Lymphoma;Journal of Clinical Medicine;2024-08-13

4. Combination of rituximab and methotrexate followed by rituximab and cytarabine in elderly patients with primary central nervous system lymphoma;British Journal of Haematology;2024-08-05

5. The Baseline Pan-Immune‑Inflammation Value (PIV) and PILE in Predicting Clinical Outcomes and Therapeutic Response for Primary Central Nervous System Lymphoma;Journal of Inflammation Research;2024-08